Q2 Revenue Beats, Full-Year Guidance Raised on Minimally Invasive Platform Adoption
ESTA has more than doubled off its 52-week low of $33.35.
Summary
Q2 revenue grew 31.7% to $67.54M, beating the $65.77M consensus, driven by accelerating adoption of its minimally invasive platform and higher-margin U.S. business. The company raised full-year 2026 revenue guidance to $269M-$271M, signaling confidence in sustained momentum. Operating leverage is evident with adjusted expenses up only 2% against that revenue growth. The bottom-line miss on EPS ($0.39 vs $0.34 consensus) reflects ongoing investment, but the top-line beat and raised outlook are the dominant signals for traders.
At the time of this announcement, ESTA was trading at $91.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $33.35 to $97.59. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.